Derek Haaland

May 17, 2023 | onlinelibrary.wiley.com | Yoshiya Tanaka |Tsutomu Takeuchi |Stephen Hall |Derek Haaland

ORIGINAL ARTICLE Yoshiya Tanaka and Tsutomu Takeuchi are co-first authors. Abstract Aim Certolizumab pegol (CZP), an Fc-free, PEGylated tumor necrosis factor inhibitor (TNFi), has shown rapid and sustained reduction in signs and symptoms of rheumatoid arthritis (RA). Elevated rheumatoid factor (RF) level has been associated with RA disease progression and poorer TNFi response. We assessed the efficacy of CZP in patients with early and established RA across baseline RF levels.